On March 11, 2026, Solid Biosciences Inc. reported positive interim results from its SGT-003 clinical trial for Duchenne muscular dystrophy, showing 44% reduction in a key biomarker after treatment. The trial involved 40 participants, and results indicated effective muscle stability with ongoing patient dosing.